Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus axitinib as second-line therapy for advanced renal cancer
ChiCTR2400094736Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and axitinib in renal cell carcinoma (RCC), sponsored by Shandong First Medical University. Primary endpoint: progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
adebrelimabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2400094736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094736.